Table 4.
Abnormalities of CF women’s and men’s pulmonary HRCTs taken before treatment.
| HRCT Features | Female (n = 13) |
Male (n = 21) |
|---|---|---|
| Nodules | 10 77% |
15 71% |
| Ground-Glass Opacities | 12 * 92% |
11 * 52% |
| Micronodules | 9 69% |
13 62% |
| Paraseptal/Centrolobular Emphysema | 4 * 31% |
14 * 67% |
| Bronchial Wall Thickening | 7 54% |
11 52% |
| Parenchymal Bands | 4 31% |
12 57% |
| Interlobular Septal Thickening and/or Reticulation | 6 46% |
8 38% |
| Mediastinal Lymphadenopathy | 4 31% |
10 48% |
| Paracicatricial Emphysema | 2 15% |
9 43% |
| Cavities | 4 31% |
6 29% |
| Architectural Distortion | 1 8% |
5 24% |
| Consolidation | 3 23% |
3 14% |
| Pleural Effusion | 1 8% |
2 10% |
| Pleural Thickening | 0 0% |
2 10% |
* p < 0.05.